Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myricetin is a naturally occurring flavonoid belonging to the flavonol class of polyphenolic compounds. It is widely found in various plants, including medicinal herbs, vegetables, berries, and tea leaves[1][5][7]. Myricetin exhibits diverse biological activities such as antioxidant, anticancer, antidiabetic, anti-inflammatory, and immunomodulatory effects[2][3][4]. Mechanistically, it acts as a potent free radical scavenger at low concentrations but can display pro-oxidant effects at higher doses[2]. Myricetin has been shown to inhibit angiogenesis by downregulating VEGF secretion via the Akt/p70S6K/HIF-1α pathway and induce apoptosis in cancer cells through mitochondrial pathways[3][8]. In neurological models (e.g., multiple sclerosis), it promotes Nrf2-mediated antioxidative signaling and supports myelination[5]. Recent studies indicate that myricetin inhibits human Uba1 (ubiquitin-like modifier activating enzyme 1) by binding to its ATP-binding site and blocking ubiquitin transfer—suggesting potential for cancer therapy targeting protein ubiquitination pathways[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myricetin.